| 肿瘤化疗导致的中性粒细胞减少诊治专家共识（2019年版） |
| |
| 引用本文： | 中国抗癌协会肿瘤临床化疗专业委员会,中国抗癌协会肿瘤支持治疗专业委员会. 肿瘤化疗导致的中性粒细胞减少诊治专家共识（2019年版）[J]. 中国肿瘤临床, 2019, 46(17): 876-882. DOI: 10.3969/j.issn.1000-8179.2019.17.913 |
| |
| 作者姓名： | 中国抗癌协会肿瘤临床化疗专业委员会 中国抗癌协会肿瘤支持治疗专业委员会 |
| |
| 摘 要： | 肿瘤化疗导致的中性粒细胞减少是化疗常见的不良反应，其有可能导致化疗药物剂量降低、化疗时间延迟乃至粒细胞减少性发热（febrile neutropenia，FN）和感染，从而增加治疗费用、降低化疗效果和生存质量，影响患者预后。正确评估化疗导致中性粒细胞减少的发生风险，早期识别FN和感染，进行合理的预防和治疗，对提高抗肿瘤治疗整体疗效、降低死亡风险等方面具有重要的意义。基于相关循证医学证据和专家共识，中国抗癌协会肿瘤临床化疗专业委员会和肿瘤支持治疗专业委员会制订了《肿瘤化疗导致的中性粒细胞减少诊治专家共识（2019版）》，旨在为中国肿瘤学医师提供更合理的诊疗方案。
|
| 关 键 词： | 中国抗癌协会 专家共识 化疗导致的中性粒细胞减少 粒细胞减少性发热 粒细胞集落刺激因子 |
| 收稿时间： | 2019-08-06 |
Consensus on the clinical diagnosis,treatment, and prevention of chemotherapy-induced neutropenia in China (2019 edition) |
| |
| Abstract: | Chemotherapy-induced neutropenia (CIN) is a common adverse reaction induced by chemotherapy. CIN may lead to dose reduction, delayed chemotherapy, and even febrile neutropenia (FN) and infection. This can result in increased cost of treatment, reduced chemotherapy efficacy, reduced quality of life, and poor prognosis. Risk assessment of CIN, early detection of FN and infection, and appropriate prevention and treatment play a crucial role in improving anti-tumor efficacy and reducing the mortality risk. Based on the available evidence and expert opinion, the expert committee of the Chinese Anti-Cancer Association issued a consensus on the diagnosis and treatment of CIN in China (2019 edition), with the aim of supporting China oncologists in the diagnosis and treatment of CIN. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
